Predictive value of mucosal TNF-α transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 65-70

  Schmidt, Carsten ^a   Giese, Thomas ^b   Hermann, Eva ^c   Zeuzem, Stefan ^c   Meuer, Stefan C ^b   Stallmach, Andreas ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Crohn's disease; Inflammatory bowel disease; Prediction; Real time polymerase chain reaction; Response

Indexed keywords

AZATHIOPRINE; CALGRANULIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23P19; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE INFLAMMATORY PROTEIN 2ALPHA; MESALAZINE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE BIOPSY; INTESTINE MUCOSA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RELAPSE; REMISSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHEMOKINES; CROHN DISEASE; CYCLOPHOSPHAMIDE; CYTOKINES; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846134376     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20012     Document Type: Article

References (39)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Sandborn WJ, Feagan BG. Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's. Gastroenterology. 2002;122:512-530.
3. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology. 1986;91:1490-1494.
4. Seegers D, Bouma G, Pena AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2002;16(Suppl 4):53-58.
5. Straub RH, Vogl D, Gross V, et al. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998;93:2197-2202.
6. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
7. van Hees PA, van Elteren PH, van Lier HJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut. 1980;21:279-286.
8. Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 1989;30:1236-1240.
9. Turnbull GK, Vallis TM. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol. 1995;90:1450-1454.
10. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30:503-512.
11. Giulietti A, Overbergh L, Valckx D, et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25:386-401.
12. Chan RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003;48:1326-1331.
13. Munoz-Valle JF, Vazquez-Del Mercado M, Garcia-Iglesias T, et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immumol. 2003;131:377-384.
14. Straubinger RK, Greiter A, McDonough SP, et al. Quantitative evaluation of inflammatory and immune responses in the early stages of chronic Helicobacter pylori infection. Infect Immun. 2003;71:2693-2703.
15. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2820-2828
16. Autschbach F, Giese T, Gassler N, et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 2002;441:500-513.
17. Stallmach A, Giese T, Schmidt C, et al. Markers for disease activity in ulcerative colitis. Digest Surg. 2003;20:350-351.
18. Stallmach A, Giese T, Schmidt C, et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal. Dis. 2004;19:308-315.
19. Schmidt C, Giese T, Ludwig B, et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis. 2005;23:1-8.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
21. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
22. Stallmach A, Wittig BM, Moser C, et al. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut. 2003;52:377-382.
23. Schmidt C, Wittig BM, Moser C, et al. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease: results of an open-labelled study. Aliment Pharmacol Ther. 2006;24:343-350.
24. Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245.
25. Nikolaus S, Raedler A, Kuehbacher T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet. 2000;356:1475-1479.
26. Agnholt J, Dahlerup JF, Buntzen S, et al. Response, relapse, and mucosal immune regulation after infliximab treatment in fistulizing Crohn's disease. Aliment Pharmacol Ther. 2003;17:703-710.
27. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123:707-713.
28. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458-1462.
29. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
30. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002;123:106-111.
31. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treament in Crohn's disease is not associated with mutations in the CARD15(NOD2) gene: an analysis in 534 patients from two multicenter, propective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
32. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scan J Gastroenterol. 2002;37:818-824.
33. Gonzalez S, Rodrigo L, Martinez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's disease patients with fistulizing disease. Am J Gastroenterol. 2003;98:1101-1106.
34. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics. 2004;5:479-486.
35. Schreiber S, Nikolaus S, Hampe J. et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999;353:425-426.
36. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol. 2002;97:2350-2356.
37. Andus T, Herfarth H, Obermeier F, et al. Prediction of response to treatment with infliximab (Rernicade) in a German prospective openlabel multicenter trial in refractory Crohn's disease. Gastroenterology. 2001;120:A621.
38. Louis E, Belaiche J, van Kemseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol. 1997;9:929-930.
39. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammtory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005;17:547-557.